retatrutide dosing clinical trial retatrutide dose for weight loss: Study shows 30% body weight loss What is the recommended dosing

Previously, GLP-1 medications which mimic the naturally occurring hormone glucagon-like peptide-1, which regulates blood sugar, digestion, and hunger had been approved only to treat obesity in the form of weekly, home-administered injections

Notably, nearly 50% of the retatrutide phase 2 obesity trial were men, which is higher than in phase 3 clinical trials with tirzepatide (32.5% in SURMOUNT-1 [27]) and semaglutide 2.4 mg (25.9% in STEP-1 [8])

NASH GLP-1

In hindsight it can be hard to believe the magnitude of such mistakes, and partly because institutions tend to bury such decisions under layers of rubble, for obvious business and psychological reasons, Lowe wrote in Science